Effect of itraconazole on the pharmacokinetics of atorvastatin

[1]  U. Christians,et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[2]  P. Neuvonen,et al.  Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.

[3]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[4]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[5]  P. Neuvonen,et al.  Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole , 1997, Clinical pharmacology and therapeutics.

[6]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[7]  D. McTavish,et al.  Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. , 1997, Drugs.

[8]  M. Radtke,et al.  Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[9]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[10]  U. Christians,et al.  Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. , 1996, Transplantation proceedings.

[11]  I. Vandewiele,et al.  Drug-interaction-induced rhabdomyolysis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[13]  T. Leemann,et al.  In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)‐fluvastatin , 1995, Clinical pharmacology and therapeutics.

[14]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[15]  P. Neuvonen,et al.  Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. , 1995, Clinical pharmacology and therapeutics.

[16]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam. , 1993, Clinical pharmacology and therapeutics.

[17]  W. Jusko,et al.  Pharmacokinetics of reversible metabolic systems , 1993, Biopharmaceutics & drug disposition.

[18]  F. Brunner‐Ferber,et al.  Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans , 1992, Journal of clinical pharmacology.

[19]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[20]  B. Arison,et al.  In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[21]  J. Tobert.  Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.

[22]  D. Illingworth,et al.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. , 1988, The New England journal of medicine.

[23]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[24]  A. Edebo,et al.  Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. , 1990, Journal of chromatography.